Ruxolitinib, 1 mg

Supplied by STEMCELL Technologies as a 1 mg unit, this selective small-molecule inhibitor targets JAK1 and JAK2 kinases, making it a routine reagent in signal transduction research. Ruxolitinib is widely used in biomedical laboratories to interrogate the JAK/STAT signaling cascade, dissect cytokine-driven cellular responses, and model myeloproliferative neoplasms in vitro. The compound is typically reconstituted in DMSO for cell culture assays, biochemical kinase studies, and flow cytometry-based phosphoprotein analyses. For optimal stability, store at -20°C, protect from light, and minimize freeze-thaw cycles by preparing single-use aliquots. Its well-characterized selectivity profile supports comparative pharmacology work, including benchmarking against next-generation JAK inhibitors and exploring pathway cross-talk in hematology, immunology, and inflammation research.